Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19 – New England Journal of Medicine Related: RCT: Bamlanivimab plus Etesevimab reduce mortality and hospitalization in ambulatory patients with early Covid-19 (within 3 days of a positive test) who are at risk for clinical deterioration (i.e., older people, obese, diabetics, immunocompromised, with CV disease). [Preprint] RECOVERY trial finds […]

The post RCT: Subcutaneous REGEN-COV antibody combination prevented symptomatic Covid-19 infection in previously uninfected household contacts of infected persons. appeared first on Links Medicus.